Tashkent, Uzbekistan (UzDaily.com) — The European Bank for Reconstruction and Development (EBRD) is providing €15 million to support the cross-border expansion of leading Ukrainian pharmaceutical company Yuria-Pharm. The funds will be allocated to investment projects in Ukraine and Uzbekistan, strengthening the company’s position in Central Asia and enhancing its competitiveness.

In Uzbekistan, EBRD financing will be used to expand production capacity, install solar panels, and improve energy efficiency. In Ukraine, the funds will support GMP certification of production, IT infrastructure modernization, and the development of biopharmaceutical research.

Additionally, the company will launch the bioGENext educational platform to train specialists in pharmaceuticals and pharmaceutical marketing, addressing the workforce shortage caused by the war.

Jean-Marc Peterschmitt, EBRD Managing Director for Industry, Commerce, and Agribusiness, emphasized that supporting Ukraine’s private sector during wartime remains one of the bank’s key priorities.

The EBRD is Ukraine’s largest institutional investor, having invested over €22 billion in more than 600 projects. Since 2022, the bank has directed over €6 billion into the country’s real economy.